Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLLISTIM vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Ovulation induction in anovulatory women,Controlled ovarian hyperstimulation for assisted reproductive technologies,Spermatogenesis induction in men with hypogonadotropic hypogonadism
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
The terminal elimination half-life ranges from 16 to 24 hours (mean ~19 hours) following subcutaneous administration. In patients with renal impairment, half-life may be prolonged, necessitating dose adjustment.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Follitropin beta is metabolized primarily in the liver and kidneys via proteolytic degradation; no specific cytochrome P450 involvement.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Primarily renal; approximately 70% of the dose is excreted unchanged in urine. A minor fraction (less than 5%) appears in feces via biliary elimination. The remainder is metabolized via hepatic pathways to inactive metabolites.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 45-50% bound, primarily to albumin and to a lesser extent to alpha-2-macroglobulin.
92% bound primarily to albumin
Volume of distribution is approximately 0.3 L/kg (range 0.2-0.4 L/kg), consistent with distribution largely into extracellular fluid.
0.4 L/kg, indicating distribution primarily in extracellular fluid
Subcutaneous: Approximately 77% (compared to intravenous administration). Intramuscular: approximately 75%. Not available for other routes.
Oral: 85% with high first-pass effect; IM: 100%
No specific guidelines; use caution in severe impairment (e GFR <30 m L/min/1.73m²) due to limited data.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh C) due to limited data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not FDA-approved for pediatric use; off-label doses: 75-150 IU subcutaneously daily, weight-based titration (1.5-2.25 IU/kg/day) for adolescent males with hypogonadotropic hypogonadism.
Not approved for pediatric use.
Not indicated for geriatric use; no dose adjustment recommended, but limited data in elderly >65 years.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
Follistim should be used only by physicians experienced in infertility treatment. It may cause ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Serious pulmonary and vascular events have been reported.
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Ovarian hyperstimulation syndrome (OHSS) can be severe; monitor ovarian response. Risk of multiple gestation and ectopic pregnancy. Ovarian torsion and adnexal torsion reported. Thromboembolic events. Ovarian enlargement may occur. Patients with porphyria may exacerbate condition.
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Hypersensitivity to follitropin beta or any component. High levels of FSH indicating primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Ovarian cyst or enlargement unrelated to PCOS. Pregnancy. Sex hormone-dependent tumors (e.g., ovarian, breast, uterine, pituitary). Abnormal genital bleeding of undetermined origin.
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No specific food interactions are documented. Grapefruit and grapefruit juice may potentially affect hormone metabolism, though not established for Follistim; advise patients to maintain a consistent diet and report unusual changes.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
FOLLISTIM (follitropin beta) is classified as Pregnancy Category X. There is no indication for use during pregnancy. Animal studies have shown evidence of fetal abnormalities, and use is contraindicated in pregnant women. In the first trimester, exposure may cause fetal harm; however, no well-controlled studies exist. The drug is not used after conception, as its sole indication is for ovulation induction and controlled ovarian stimulation prior to assisted reproductive technologies.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
FOLLISTIM is not recommended for use during breastfeeding. It is not known whether follitropin beta is excreted in human milk. Given the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio is available.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
There are no recommended dosing adjustments for FOLLISTIM during pregnancy because the drug is contraindicated and not used in pregnancy. Pregnancy results from treatment, at which point FOLLISTIM is discontinued. No pharmacokinetic changes are studied in pregnancy as it is not administered to pregnant women.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
Follistim (follitropin beta) is a recombinant FSH used for ovulation induction and controlled ovarian stimulation. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing. Risk of ovarian hyperstimulation syndrome (OHSS) increases with high estradiol (>3000 pg/m L) and multiple follicles. Do not use in primary ovarian failure, uncontrolled thyroid/adrenal disorders, or sex hormone-dependent tumors. For subcutaneous administration; rotate injection sites.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
Follistim is injected subcutaneously exactly as prescribed; do not skip or change dose without talking to your doctor.,You will need regular blood tests and ultrasounds to monitor your response and adjust treatment.,Common side effects include injection site reactions, headache, nausea, and bloating.,Contact your doctor immediately if you experience severe pelvic pain, sudden weight gain, or difficulty breathing, which could indicate ovarian hyperstimulation syndrome (OHSS).,Follistim increases the chance of multiple pregnancy (twins, triplets).,Store vials in the refrigerator, not frozen, and protect from light. Do not use if solution is cloudy or contains particles.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLLISTIM vs ANTAGONATE, answered by our medical review team.
FOLLISTIM is a Gonadotropin that works by Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLLISTIM and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLLISTIM is: Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLLISTIM and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLLISTIM is classified as Category C. FOLLISTIM (follitropin beta) is classified as Pregnancy Category X. There is no indication for use during pregnancy. Animal studies have shown evidence of fetal abnormalities, and . ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.